Immune checkpoint inhibitors
Immunology-based therapy is rapidly developing into an effective treatment option for a surprising range of cancers. We have learned over the last decade that powerful immunologic effector cells may be blocked by inhibitory regulatory pathways controlled by specific molecules often called "immune checkpoints." The development of a new therapeutic class of drugs that inhibit these inhibitory pathways has recently emerged as a potent strategy in oncology. Three sets of agents have emerged in clinical trials exploiting this strategy. These agents are antibody-based therapies targeting cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1). These inhibitors of immune inhibition have demonstrated extensive activity as single agents and in combinations. Clinical responses have been seen in melanoma, renal cell carcinoma, small cell lung cancer, and several other tumor types.
- Drugs
- Recognision of immune cells
- Attacking mechanisms
- Adverse effects of these drugs
- Considerations in Using/Prescribing
- PD-1 or PD-L1 Targetors/Targets
- Targetting CTLA-4
Related Conference of Immune checkpoint inhibitors
5th International conference on Vaccines, Vaccination and Immunization
19th International Conference on Allergy and Clinical Immunology
5th International Conference on Immunology And Immunotherapy
Immune checkpoint inhibitors Conference Speakers
Recommended Sessions
- Antibody Therapy of Cancer
- Brain Tumors
- Cancer & HIV
- Cancer biomarkers
- Cancer clinical trials
- Cancer Genomics and Metabolomics
- Cancer Immunology & Immunotherapy
- Cancer micro and immuno environment
- Cancer Pharmacology
- Cancer Prognosis & Diagnosis
- Cancer Research & Cancer vaccines
- Combining Cancer Immunotherapies
- Immune checkpoint inhibitors
- Immuno-Oncology studies
- Novel Approaches in Cancer & Tumor
- Radiology and Imaging in Cancer
- Stem Cell Therapy
- Tumor biology
- Tumor Immunology
- Tumor immunotherapy research
- Tumor markers and drug targeting
- Tumors
- Types of cancer
Related Journals
Are you interested in
- Advances in Molecular Immunology - ALLERGY 2024 (France)
- Allergen Identification and Characterization - ALLERGY 2024 (France)
- Biomarkers for Allergy Diagnosis and Treatment - ALLERGY 2024 (France)
- Case Studies in Allergy Diagnosis and Management - ALLERGY 2024 (France)
- Clinical Trials and Translational Research in Allergy and Immunology - ALLERGY 2024 (France)
- Digital Health and Telemedicine in Allergy Care - ALLERGY 2024 (France)
- Epidemiology and Population Studies in Allergic Diseases - ALLERGY 2024 (France)
- Immune Responses to Vaccination - ALLERGY 2024 (France)
- Immunogenetics and Allergic Susceptibility - ALLERGY 2024 (France)
- Immunological Aspects of Drug Allergies - ALLERGY 2024 (France)
- Immunological Basis of Food Allergy - ALLERGY 2024 (France)
- Immunological Mechanisms in Autoimmune Diseases - ALLERGY 2024 (France)
- Immunomodulation in Allergy Management - ALLERGY 2024 (France)
- Immunopathogenesis of Allergic Diseases - ALLERGY 2024 (France)
- Immunotherapy for Allergic Conditions - ALLERGY 2024 (France)
- Inflammatory Pathways in Asthma and Allergic Rhinitis - ALLERGY 2024 (France)
- Mechanisms of Immunodeficiency Diseases - ALLERGY 2024 (France)
- Novel Therapeutic Approaches for Allergic Disorders - ALLERGY 2024 (France)
- Role of Microbiota in Allergic Disorders - ALLERGY 2024 (France)